Magnesium Sulfate in Acute Stroke: A Randomized Double-Blind Clinical Trial

Abstract

Background: Administration of magnesium sulfate has neuroprotective effects and reduces infarct volume in animal models of stroke. Previous small clinical trials have reported beneficial effect of magnesium on the outcome in patients with stroke. This study was a randomized, placebo-controlled, double-blind study , investigated the benefit of magnesium sulfate the administration given intravenously as a neuroprotective. Methods: Patients who had cortical infarction in the middle cerebral artery territory (superior or inferior division) with moderate neurologic deficits (Orgogozo scale score greater than 30 and less than 70) and onset less than 24 hours were included. The patients were treated with magnesium sulfate (4gr stat and 1gr/hr) or placebo for 4 days and examined by a blind investigator. NIH Stroke Scale was obtained on admission and fifth day after stroke. Results: Eighteen patients were given treatment and nineteen patients were given placebo who demonstrated significant beneficial effects on the difference between NIH Stroke Scales on the day of admission and day 5 (3.16 ± 0.98 vs. 1.84 ± 1.06; p = 0.000 respectively). Conclusion: Intravenous magnesium sulfate had significant beneficial effect on acute phase of stroke patients and, as a result, may reduce duration of admission. Keywords: Stroke, Magnesium sulfate, Neuroprotective.